Featured Article
With a novel pharmacogenomic platform, Leapfrog Bio is screening clinically actionable molecules to target major solid tumor markets in a condensed timeline requiring far fewer resources.
Precision Oncology Today
Magazine
Minimal Disease, Maximum Benefit
As both flow cytometry technology and genomic sequencing have taken technological leaps forward, the sensitivity and specificity of testing has increased to include MRD for solid tumors. Leveraging advances in next-generation sequencing, MRD test developers can look for thousands of disease markers and even detect one cancerous cell among a million healthy cells. This level of sensitivity provides evidence of disease recurrence months before traditional follow-up screening methods.
Immunogenomics is on the Way Up
Combining immune-system science, omics, and various computational algorithms might produce success where advanced cancer treatments have failed.
Trending on Inside Precision Medicine
New Blood Test Predicts Risk for COPD and Severe Respiratory Diseases
A team of scientists supported by the National Institutes of Health (NIH) has developed a promising blood test that could predict the risk of developing severe respiratory diseases, such as chronic obstructive pulmonary disease (COPD).
Burn Rubber: Superluminal Medicines Gets $120M to Take GPCR Drugs to Clinic
The funds will move Superluminal's lead program from animal testing to the clinic, expand the pipeline, and advance their computational and data-heavy platform.
Age-Related Changes in Fibroblasts Drive Treatment-Resistant Melanoma in Males
Research in human cells and in mice by scientists at the Johns Hopkins Kimmel Cancer Center suggests that age-related changes in fibroblasts contribute to the development of aggressive, treatment-resistant melanoma in males.